ReviewFrontiers in cell and developmental biology2026
AI-enabled multi-omics integration in colorectal cancer: from molecular stratification to clinical translation.
Review in Frontiers in cell and developmental biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The role of NADFrontiers in oncology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Colorectal cancer (CRC) remains a heterogeneous disease for which improved molecular stratification is needed across the clinical pathway. Multi-omics technologies have expanded insight into CRC biology, and artificial intelligence (AI) has created new possibilities for integrating molecular, pathological, imaging, and clinical data. This review examines how these approaches are being applied across screening, diagnosis, treatment, and prognosis, with particular emphasis on their clinical relevance and translational limitations. We argue that, despite encouraging advances in biomarker discovery and risk prediction, most current studies remain retrospective and are constrained by heterogeneity of data sources, limited standardisation, weak interpretability, and insufficient external or prospective validation. AI-enabled multi-omics integration has substantial potential in CRC, but meaningful clinical impact will require rigorous validation and implementation frameworks suited to routine care.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.